Soleno Therapeutics, Inc.
SLNO
$65.56
$2.824.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 78.46% | -104.57% | -395.59% | -605.42% | -157.86% |
| Total Depreciation and Amortization | 1.62% | 2.86% | 2.86% | 2.04% | 1.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 29.06% | 161.84% | 1,015.88% | 1,312.74% | 381.85% |
| Change in Net Operating Assets | -355.42% | -427.80% | 36.96% | 5,526.53% | -598.64% |
| Cash from Operations | 28.57% | -161.43% | -279.97% | -135.72% | -217.12% |
| Capital Expenditure | -12.50% | 54.55% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 93.46% | 119.91% | -- | -- | -- |
| Cash from Investing | 93.45% | 119.90% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -89.59% | 249.68% | -94.19% | -94.23% | 795.36% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -89.73% | 243.07% | -53.82% | -94.23% | 795.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -134.10% | 94.80% | -66.30% | -126.04% | 23.34% |